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β-alanine suppresses malignant breast epithelial
cell aggressiveness through alterations in
metabolism and cellular acidity in vitro
Roger A Vaughan1,2,3*, Nicholas P Gannon2, Randi Garcia-Smith2, Yamhilette Licon-Munoz2, Miguel A Barberena2,
Marco Bisoffi2,4,5 and Kristina A Trujillo2,4*
Abstract
Background: Deregulated energetics is a property of most cancer cells. This phenomenon, known as the Warburg
Effect or aerobic glycolysis, is characterized by increased glucose uptake, lactate export and extracellular
acidification, even in the presence of oxygen. β-alanine is a non-essential amino acid that has previously been
shown to be metabolized into carnosine, which functions as an intracellular buffer. Because of this buffering
capacity, we investigated the effects of β-alanine on the metabolic cancerous phenotype.
Methods: Non-malignant MCF-10a and malignant MCF-7 breast epithelial cells were treated with β-alanine at
100 mM for 24 hours. Aerobic glycolysis was quantified by measuring extracellular acidification rate (ECAR) and
oxidative metabolism was quantified by measuring oxygen consumption rate (OCR). mRNA of metabolism-related
genes was quantified by qRT-PCR with corresponding protein expression quantified by immunoblotting, or by flow
cytometry which was verified by confocal microscopy. Mitochondrial content was quantified using a
mitochondria-specific dye and measured by flow cytometry.
Results: Cells treated with β-alanine displayed significantly suppressed basal and peak ECAR (aerobic glycolysis),
with simultaneous increase in glucose transporter 1 (GLUT1). Additionally, cells treated with β-alanine exhibited
significantly reduced basal and peak OCR (oxidative metabolism), which was accompanied by reduction in
mitochondrial content with subsequent suppression of genes which promote mitochondrial biosynthesis. Suppression
of glycolytic and oxidative metabolism by β-alanine resulted in the reduction of total metabolic rate, although cell
viability was not affected. Because β-alanine treatment reduces extracellular acidity, a constituent of the invasive
microenvironment that promotes progression, we investigated the effect of β-alanine on breast cell viability and migration.
β-alanine was shown to reduce both cell migration and proliferation without acting in a cytotoxic fashion. Moreover,
β-alanine significantly increased malignant cell sensitivity to doxorubicin, suggesting a potential role as a
co-therapeutic agent.
Conclusion: Taken together, our results suggest that β-alanine may elicit several anti-tumor effects. Our observations
support the need for further investigation into the mechanism(s) of action and specificity of β-alanine as a
co-therapeutic agent in the treatment of breast tumors.
Keywords: Warburg metabolism, Glycolysis, Carnosine, Mitochondria, Oxidative metabolism, Proliferation,
Migration, Doxorubicin
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Introduction
A multitude of factors influence cancer aggressiveness
and invasiveness, many of which may be targeted by
chemical agents as therapies [1]. Recent studies on can-
cer metabolism have revealed potential therapeutic targets
that may slow cancer progression through restoration of
a more normal metabolic phenotype [2-4]. Enhanced
glucose uptake and aerobic glycolysis within tumors are
well-document properties of tumor cell metabolism.
Although increased glucose uptake has been exploited
as a tool in early diagnostics such as in PET scan using
18F-deoxyglucose, heightened glycolytic reliance within
tumor cells may provide numerous advantages to tumor
cells [1,5].
One mechanism though which aerobic glycolysis may
contribute to tumor aggressiveness is through acidification
of the extracellular environment. For example, functional
proteases are essential to tumor cell migration and invasion
through tissue matrices. These proteases are dependent in
great part on extracellular acidification, a direct function of
cellular lactate export which is exacerbated in malignant
phenotypes [6]. Furthermore, the acidic microenvironment
of tumors can affect the efficacy of chemotherapeutic
agents. For instance, the cellular uptake of Doxorubicin
(Dox), an anthracycline which impedes tumor growth
through DNA intercalation [7], is significantly affected by
extra and intracellular pH. Dox acts as a weak base, and
under protonated conditions is less able permeate to
membranes [7,8]. Increased extracellular acidity such as
that produced by aerobic glycolysis, reduces Dox uptake
and alters cellular distribution leading to impaired efficacy
[7,8]. Reduction of acidity has previously been shown to
enhance both the uptake and toxicity of Dox in the malig-
nant MCF-7 breast epithelial cell model [8].
β-alanine (3-aminopropanoic acid) is a non-essential
amino acid found as a principal component of several
commercially available sports supplements that purport-
edly increase athletic performance [9,10]. This is pro-
posed to occur by the combination of β-alanine with
histidine to form carnosine, which functions as an intra-
cellular buffer [10]. Supplementation with β-alanine has
been shown to delay accumulation of lactate during ex-
ercise through buffering the formation of lactate from
pyruvate [10]. In cancer, the formation of carnosine is
thought to be an under-explored agent with potentially
therapeutic benefits [4]. Specifically, carnosine accumu-
lation has been shown to reduce the proliferation of cul-
tured of tumor cells and reduce tumor growth in vivo
[4,11-13]. It is hypothesized that carnosine accumulation
inhibits glycolysis, limiting energy production [4]. Add-
itionally, carnosine has been shown to reduce cellular ATP
production in glioma cells, and it is postulated that bene-
fits of carnosine towards tumor inhibition are in part a re-
sult of glycolytic inhibition [4,14,15].
We demonstrate for the first time that treatment of
breast epithelial cells with β-alanine reduces cancerous
metabolism in addition to reducing extracellular acidifica-
tion leading to suppressed aggressiveness. Furthermore,
we demonstrate that β-alanine can increase the efficacy of
Dox on MCF-7 cells at low concentrations.
Methods
Cell culture and treatments
Non-malignant breast epithelial cells (MCF-10a) and ma-
lignant breast epithelial cells (MCF-7) were purchased
from ATCC (Manassas, VA). MCF-10a cells were cultured
in combination F-12 DMEM media supplemented with
50 nM hydrocortisone, 20 ng/ml EGF, 0.01 mg/ml human
insulin, 5% fetal bovine serum (FBS), and 1% Pen-Strep.
MCF-7 cells were cultured in DMEM supplemented with
10% FBS with 0.01 mg/ml human insulin, and 1% Pen-
Strep. Cells were treated with β-alanine from Sigma (St.
Louis, MO) at 100 mM dissolved in media and incubated
in 5% CO2 at 37°C for 24 hours.
Metabolic assay
Cells were seeded overnight in 24-well culture plate
from SeaHorse Bioscience (Billerica, MA) at density 5 ×
105 cells/well. To control for nitrogen load and hyper-
osmolality, we also treated control cells with isonitrogen-
ous valine or D-alanine. Following treatment, culture media
was removed and replaced with XF Assay Media from Sea-
Horse Bioscience (Billerica, MA) containing 4500 mg/L
glucose free of CO2 and incubated at 37°C. Per manufac-
tures’ protocol, SeaHorse XF24 Extracellular Analyzer in-
jection ports were loaded with oligomycin, an inhibitor of
ATP synthase which induces maximal glycolytic metabol-
ism and reveals endogenous proton leak (mitochondrial
uncoupling) at a final concentration 1.0 μM. Measure-
ment with oligomycin were taken for 24 minutes followed
by the addition of carbonyl cyanide p-[trifluoromethoxy]-
phenyl-hydrazone (FCCP), an uncoupler of electron trans-
port that induces peak oxygen consumption (an indirect
indicator of peak oxidative metabolism) at final concentration
1.25 μM. FCCP measurements were taken for 24 minutes
followed by rotenone addition in 1.0 μM final concentra-
tion to reveal non-mitochondrial respiration and end the
metabolic reactions [16,17]. Extracellular acidification rate
(ECAR) calculated from proton production rate is an in-
direct measure of glycolytic capacity. Oxygen consumption
(OCR), a measure of oxidative metabolism was measured
using the SeaHorse XF24 Extracellular Analyzer from Sea-
Horse Bioscience (Billerica, MA). SeaHorse XF24 Extra-
cellular Analyzer was run using 8 minute cyclic protocol
commands (mix for 3 minutes, let stand 2 minutes, and
measure for 3 minutes) as previously described [18,19].
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Cellular ATP content
Following treatment as described above, buffer-free media
was added to the cells to measure total ATP production.
The cells were lysed in 1% CHAPS lysis buffer from
Chemicon (Billerica, MA) in PBS with Ca2+ and Mg2+ and
the ATP-containing supernatant was recovered. Samples
were allocated into a 96-well plate with a 1:1 dilution of
ATP Bioluminescence Reagent from Sigma (St. Louis, MO)
and ATP-containing samples (final reaction volume =
100 μl) and luminescence was measured as previously
described [18].
Quantitative real time polymerase chain reaction
(qRT-PCR)
Following incubation, the total RNA was extracted using
RNeasy Kit from Qiagen (Valencia, CA), per manufac-
turer’s protocol. Total RNA was quantified by Nanodrop
spectrophotometry. cDNA was synthesized from 5000 ng
total RNA using the Retroscript™ RT kit from Ambion
(Austin, TX) according to manufacturer’s instructions.
PCR primers were designed using Primer Express software
from Invitrogen (Carlsbad, CA) and synthesized by Inte-
grated DNA Technologies (Coralville, IA). Amplification
of glucose transporter 1 (GLUT1), lactate dehydrogenase
(LDH), and peroxisome proliferator-activated receptor
gamma coactivator 1 alpha (PGC-1α) were normalized to
the housekeeping gene, TATA Binding Protein (TBP).
Table 1 summarizes the forward and reverse primers of
each gene. qRT-PCR reactions were performed in tripli-
cate using the LightCycler 480 real-time PCR system from
Roche Applied Science, (Indianapolis, IN). SYBR Green
based PCR was performed in triplicate using 5000 ng of
cDNA per sample; final primer concentrations were
10 μM in a total volume of 30 μl. The following cycling
parameters were used: 95°C for 10 minutes followed by
45 cycles of 95°C for 15 seconds, and 60°C for one mi-
nute. Relative expression levels were determined by the
ΔΔCp method and compared to the lowest expressing
group as previously described [18,20,21].
Flow cytometry
Following treatment, the media was removed and the cells
were re-suspended in pre-warmed media with 200 nM
Mitotracker Green from Life Technologies (Carlsbad, CA)
and incubated for 45 minutes as described above. The
cells were pelleted, the media with Mitotracker was re-
moved and the cells were suspended in pre-warmed
media. Group mean fluorescence was measured using
Facscalibur filtering 488 nm as previously performed [18].
To quantify protein expression, cells were treated as de-
scribed before, trypsinized, permeabilized and blocked for
1 hour with PBS with 0.1% Triton 100X and 3.0% BSA
from Sigma (St. Louis, MO). Cells were stained overnight
with anti-GLUT1 antibodies (SPM498, mouse monoclo-
nal) from Abcam (Cambridge, MA) at a final concentra-
tion of 1 μg/ml in PBS containing 0.1% BSA. The cells
were rinsed with PBS with 0.1% Triton 100X and 3.0%
BSA, and a secondary antibody (either AlexFluor 488
from Invitrogen (Carlsbad, CA)) was applied in 1:200 di-
lution for 1 hour [22]. Cells were then rinsed and re-
suspended in PBS and the fluorescence was quantified
as described above.
Microscopy and immunocytochemistry
Chamber-slides from BD Bioscience (Sparks, MD), were
seeded with 5000 cells/well. To verify protein expression,
cells were cultured and treated for 24 hours as described
above. Cells were fixed using 3.7% formaldehyde in
media, permeabilized with PBS with 0.1% Triton 100X
from Sigma (St. Louis, MO) for 10 minutes and blocked
for 1 hour with PBS with 0.1% Triton 100X and 3.0%
BSA from Sigma (St. Louis, MO). Cells were stained
overnight with anti-GLUT1 antibodies (SPM498, mouse
monoclonal) from Abcam (Cambridge, MA) at a final
concentration of 1 μg/ml in PBS containing 0.1% BSA.
The cells were rinsed with PBS with 0.1% Triton 100X
and 3.0% BSA, and an AlexFluor 633 from Invitrogen
(Carlsbad, CA) was applied in 1:200 dilution. Slides were
mounted with Prolong Gold with DAPI from Invitrogen
(Carlsbad, CA) and cured overnight. Cells were imaged
using the Axiovert 25 microscope with AxioCam MRc
from Zeiss (Thornwood, NY).
Western blotting
Whole-cell lysates were collected following 24 hour
treatment. Whole cell lysates were prepared by harvesting
the cells on ice in high salt lysis buffer (25 mM Tris base,
8 mM MgCl2, 1 mM DTT, 15% glycerol, 0.1% Triton)
Table 1 Summary of qRT-PCR primers from integrated DNA technologies (Coralville, IA)
Primer name Forward sequence Reverse sequence
GLUT1 5′-ATCGTGGCCATCTTTGGCCTTT-3′ 5′-CTGGAAGCACATGCCCACAAT-3′
LDH 5′-GCCCGTTTCCGTTACCTAAT-3′ 5′- CTCCATAAGGGCACACTAGAATC-3′
PGC-1α 5′-ACCAAACCCACAGAGAACAG-3′ 5′-GGGTCAGAGGAAGAGATAAAGTTG-3′
TBP 5′-CACGAACCACGGCACTGATT-3′ 5′-TTTTCTTGCTGCCAGTCTGGAC-3′
Abbreviations: Glucose transporter 1 (GLUT1), lactate dehydrogenase (LDH), peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α), and
TATA binding protein (TBP).
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supplemented with protease inhibitor mix (Sigma, St. Lois
MO), followed by incubation on ice for 60 minutes. Insol-
uble material was removed by centrifugation at 17,500 × G
for 3 minutes and protein concentrations were determined
by Bradford assay (Protein Assay Dye Reagent Concentrate,
Bio-Rad Laboratories, Hercules, CA). Total protein (120 μg
per sample) was size-separated by 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and electro-transferred to nitrocellulose membranes. After
blocking in TBST-5% non-fat milk powder for 1 hour,
membranes were probed at 4°C for 24 hours with an anti-
PGC-1α antibody from Santa Cruz Biotechnologies (Santa
Cruz, CA), anti-GLUT1, anti-carnosine synthase (CS),
or anti-lactate dehydrogenase (LDH) antibodies from
Abcam (Cambridge, MA), normalized to an anti-β-actin
primary monoclonal antibody from Sigma (St. Louis, MO)
in TBST-1% non-fat milk powder overnight. Bound anti-
bodies were detected by horseradish peroxidase-conjugated
secondary antibodies from Sigma (St. Louis, MO) and by
chemiluminescence using the ECL Plus Western Blotting
Detection kit from GE Healthcare Life Sciences (Little
Chalfont, Buckinghamshire, UK). Signal intensities were
obtained by densitometry using ImageJ software (available
from the NIH at http://rsbweb.nih.gov/ij/) by quantifying
lane intensities followed by normalizing intensity with cor-
responding β-actin.
Cell proliferation, migration and viability
Cell proliferation was assessed by measuring confluence-
mask quantification via phase-contrast Incucyte ZOOM
live content imaging and cell surveillance from Essen Bio-
science (Ann Arbor, MI) in a 96-well plate. Cells were re-
suspended in respective growth media with and without
β-alanine at 100 mM, incubated and confluency was mea-
sured every hour for 48 hours. Cell migration was assessed
by applying a standard scratch through confluent cells fol-
lowing treatment for 24 hours. The cells were then rinsed
and the media replaced with corresponding treatments
(control or β-alanine at 100 mM). Migration was deter-
mined by measuring the change in confluency for 24 hours
following the initial wound. To assess changes in viability,
cells were seeded overnight, and treated and incubated as
described above for either 24 or 48 hours. The cells were
then incubated for 1 hour in medium containing 10% WST-
1 cell proliferation reagent from Roche (Indianapolis, IN)
and fluorescence was measured using a Wallac Victor3V
1420 Multilabel Counter from PerkinElmer (Waltham,
MA). To further investigate the effects of β-alanine on cell
survival, cells were treated with varying concentrations
(from 10 pM – 10 μM) of the antineoplastic Dox (in DMSO
with final concentration = 0.1% for all Dox experiment
groups including control) from Sigma (St. Louis, MO) with
and without β-alanine at 100 mM for 24 hours. Treatment
doses and duration were determined through pilot data for
β-alanine and from previous observations for Dox [23].
Statistical analyses
Metabolic measurements were analyzed by ANOVA with
Tukey’s pair-wise comparisons for β-alanine compared
with various controls. ATP concentration, cell migration,
proliferation, immunoblotting, as well as flow cytometry
and microscopy were analyzed using student’s t-test. Gene
expression was quantified by relative expression using the
ΔΔCp method, and analyzed using student’s t-test [18,20].
Cell viability was analyzed using analysis of variance
(ANOVA) with Dunnett’s post hoc test. All data is repre-
sented as average ± standard deviation (SD) normalized to
the control mean (control = 100) with *, **, and *** indicat-
ing p < 0.05, p < 0.01, and p < 0.001 statistical differences
compared to control, respectively.
Results
β-alanine reduces glycolytic metabolism
To investigate the effects of β-alanine on aerobic glycolysis,
we measured extracellular acidification rate (ECAR) fol-
lowing treatment for 24 hours. Both malignant (MCF-7)
and non-malignant (MCF-10a) cells treated with β-alanine
exhibited significantly reduced basal glycolysis compared
with both true control and equivocal nitrogen load from
100 μM valine (Figure 1A). Additionally, β-alanine-treated
MCF-7 cells demonstrated significantly reduced peak glyco-
lytic capacities (peak glycolysis induced by oligomycin)
compared with respective controls, but was unchanged
in MCF-10a cells (Figure 1B). Similarly, both cell mo-
dels exhibited significantly reduced cellular acidity fol-
lowing treatment with β-alanine compared with both
true negative and valine control (Figure 1C).
To investigate the effects of β-alanine on oxidative me-
tabolism, we measured oxygen consumption rate following
treatment for 24 hours. Both MCF-7 and MCF-10a cells
treated with β-alanine exhibited significantly reduced basal
oxidative metabolism, however both D-alanine and L-
valine controls were significantly reduced in the MCF-
10a (Figure 1D). In addition to suppressed oxidative
metabolism, MCF-10a cells exhibited increased oxida-
tive reliance (expressed as a ratio of oxidative metabol-
ism to glycolytic metabolism) illustrated in Figure 1E.
Surprisingly, β-alanine-treated MCF-10a cells had sig-
nificantly elevated total ATP content compared with
their control, while MCF-7 ATP content was signifi-
cantly reduced (Figure 1F).
β-alanine alters glycolytic-related gene expression
To investigate the effects of β-alanine on gene expression
related to aerobic glycolysis, we first measured LDH fol-
lowing treatment for 24 hours. Both MCF-7 and MCF-10a
cells treated with β-alanine exhibited significantly reduced
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LDH mRNA levels while neither cell model exhibited
significantly altered protein expression (Figure 2A and
B, respectively). Because one potential mechanism of ac-
tion of β-alanine could be through carnosine produc-
tion, we measured Carnosine Synthase (CS) expression.
CS was present in both cell models, but unaltered by
β-alanine treatment (Figure 2C). In agreement with
RNA levels, GLUT1 protein expression was significantly
elevated in MCF-10a cells treated with β-alanine com-
pared with control (measured by flow cytometry) which
was verified by confocal microscopy (Figure 2D).
β-alanine alters oxidative gene expression and
mitochondrial content
In order to evaluate the effects of β-alanine treatment on
expression of genes involved in oxidative metabolism, we
performed qRT-PCR following 24 hours treatment. Both
β-alanine treated cell models demonstrated significantly
suppressed RNA expression of PGC-1α (Figure 3A).
Interestingly, PGC-1α protein expression was sup-
pressed in MCF-7 cells but was unaltered in MCF-10a
cells (Figure 3B). Consistent with PGC-1α protein expres-
sion, mitochondrial content was also suppressed in MCF-7
cells but was unaltered in MCF-10a cells (Figure 3C).
β-alanine inhibits cellular proliferation without reducing
viability and increases chemo-sensitivity
In order to assess changes in cellular growth, we mea-
sured the effect of β-alanine on both cell models follow-
ing treatment for either 24 or 48 hours. Proliferation of
MCF-7 and MCF-10a was significantly suppressed fol-
lowing growth in media containing β-alanine compared
with control (Figure 4A and B, respectively). Neither cell
model experienced significant changes in cell viability at
any of the tested doses (Figure 4C and D). To evaluate
the effect β-alanine on cell migration, we measured cell
motility via scratch-wound migration assay in a live cell
imager taken hourly images for 48 hours. In both cell
models, β-alanine treatment significantly reduced mi-
gration velocity compared with corresponding controls
(Figure 5A and B). Because cellular uptake of Dox is sig-
nificantly influenced by intra and extracellular pH, we in-
vestigated the effect of β-alanine on the efficacy of Dox.
We treated MCF-7 cells with varying concentrations of
Dox with and without β-alanine at 100 mM for 24 hours.
Dox plus β-alanine treatment significantly reduced MCF-
7 viability at all doses tested compared with DMSO con-
trol, an effect which was not seen in the Dox-only groups
until high concentrations (1 μM -10 μM) (Figure 6). There
Figure 1 β-Alanine alters glycolytic and oxidative metabolism in breast epithelial cells. (A) Basal glycolytic metabolism reported as
extracellular acidification rate (ECAR) following treatment of either MCF-7 or MCF-10a cells with β-Alanine, D-Alanine, or L-Valine at 100 mM for
24 hours. (B) Peak glycolytic metabolism (induced with oligomycin) for cells following treatment as described above. (C) Proton production rate
during basal metabolism. (D) Basal oxidative metabolism reported as oxygen consumption rate (OCR) following treatment as described above.
(E) Oxidative reliance expressed as a ratio of OCR:ECAR. (F) Cellular ATP production of both cell models following treatment as described above.
NOTES: *indicates P < 0.05, **indicates P < 0.01, ***indicates P < 0.001 compared with control. v indicates P < 0.05 compared with L-Valine control.
a indicates P < 0.05 compared with D-Alanine control.
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were also significant reductions in MCF-7 viability at low
doses of Dox with simultaneous β-alanine treatment.
These observations suggest that β-alanine sensitizes can-
cer cells to Dox, thus improving the efficacy at lower
concentrations.
Discussion
Deregulated cellular energetics is now recognized as an
emerging hallmark of cancer, central to most cancer pheno-
types for reasons that remain elusive. In this report, we
demonstrate that β-alanine, a commercially available prod-
uct that exhibits intracellular buffering capacity, alters
metabolic characteristics of malignant and non-malignant
breast epithelial cells. Our experiments demonstrate that β-
alanine can significantly reduce glycolytic metabolism with
simultaneous reduction in corresponding cellular acidity.
Additionally, we illustrate that β-alanine can selectively and
significantly reduce oxidative metabolism by diminishing
mitochondrial content in malignant cells. These results
taken together demonstrate that β-alanine treatment can
result in significantly suppressed basal metabolism; a poten-
tially meaningful observation in cancer therapeutics.
Cells treated with β-alanine presented a favorable change
in the microenvironment by increasing the alkalinity of the
cellular microenvironment. These findings are consistent
with previous observations that β-alanine consumption in
humans increases blood pH and buffers lactate in anaer-
obically contracting muscle cells [10,24]. As mentioned
above, extracellular pH plays a central role in regulation
and activation of proteases used by malignant cells during
migration and invasion [25,26].
Of interest are the effects that β-alanine or its metab-
olite carnosine may exhibit on tumor progression, which
has been most heavily studied in neural cells [4]. Al-
though oral administration of β-alanine increases carno-
sine content of select tissues (such as skeletal muscle), a
Figure 2 β-Alanine alters glycolytic related gene expression in breast epithelial cells. (A) Lactate dehydrogenase (LDH) RNA induction by
qRT-PCR of MCF-7 and MCF-10a cells following treatment with either media control or 100 mM β-Alanine for 24 hours. (B) LDH protein expression
following treatment as described above (representative blots displayed in E). (C) Carnosine synthase (CS) protein expression following treatment as
described above (representative blots displayed in E). (D) GLUT1 RNA induction (left) and GLUT1 protein expression quantified via confocal microscopy
(center) or flow cytometry (right). Microscopy was quantified using 3 images and 7 representative cells/treatment. (E) Representative immunoblots and
confocal microscopy images of MCF-7 cells (left) and MCF-10a cells (right) following treatment as described above (Blue = DAPI, Red = GLUT1, Green
Size Bar = 50 μm). Images were taken using 63 × magnification with oil emersion. NOTES: *indicates P < 0.05, **indicates P < 0.01, ***indicates P < 0.001
compared with control.
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concerning obstacle is that β-alanine treatment will only
elicit anti-tumor effects in selective tissues that express
carnosine synthase, suggesting that β-alanine’s benefits
may be highly discriminatory [4,27]. While we demon-
strate that both of the tested cell models express carnosine
synthase, β-alanine treatment does not appear to alter
carnosine synthase expression. This does not conclusively
demonstrate that β-alanine-treated cells have equivocal
carnosine content to untreated controls, but one might
expect heightened carnosine synthase expression if it were
a primary mechanism of action in β-alanine-treated cells.
It is also interesting that our observations show that β-
alanine treatment can reduce metabolism and prolifera-
tion in breast epithelial cells (similar to previous results
in glioma cells), without significantly altering cell viabil-
ity [11-14]. A limitation of these observations is that β-
alanine treated cells were tested in glucose-rich media,
in which glucose was the primary substrate. If β-alanine
Figure 4 β-Alanine suppresses breast epithelial cell proliferation without altering cell viability. (A) Culture confluency of MCF-7 cells
following treatment with control (−) or 100 mM β-Alanine (+) for 24 hours as measured by phase contrast live cell imaging. (B) Culture confluency of
MCF-10a cells following treatment as described above. (C) Cell viability of MCF-7 cells treated as described above. (D) Cell viability of MCF-10a cells
treated as described above. NOTES: *indicates P < 0.05, **indicates P < 0.01, ***indicates P < 0.001 compared with control.
Figure 3 β-Alanine selectively suppresses mitochondrial content and related gene expression in malignant breast epithelial cells. (A)
PGC-1α mRNA induction measured by qRT-PCR of MCF-7 and MCF-10a cells treated with and without β-Alanine for 24 hours. (B) PGC-1α protein
expression following treatment as described above (representative blots displayed in D). (C) Mitochondrial content measured by flow cytometry
following Mitotracker green staining of MCF-7 and MCF-10a cells treated with and without β-Alanine for 24 hours. (D) Representative immunoblots of
MCF-7 cells (left) and MCF-10a cells (right). NOTES: *indicates P < 0.05, **indicates P < 0.01, ***indicates P < 0.001 compared with control.
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inhibits glycolytic metabolism, then it is conceivable that
β-alanine could reduce oxidative metabolism purely as a
function of limited available substrate for oxidative me-
tabolism. Hence, β-alanine may suppress oxidative me-
tabolism by way of substrate blockade. In contrast to
this hypothesis, we showed that β-alanine selectively re-
duces mitochondrial content in malignant MCF-7 cells
by means of PGC-1α suppression; however this may
only contribute some of the observed reductions in oxi-
dative metabolism.
Also of great interest is the observation that β-alanine
increases malignant breast cell sensitivity to Dox. Al-
though not a clinical observation, our data further im-
plicates β-alanine as a candidate for adjuvant therapy in
malignancies such as breast cancer. Specifically, the ob-
servation that Dox plus β-alanine causes significantly
reduced viability with extremely low concentrations of
Dox (i.e. 10pM) suggesting combination therapy may
lead to lower therapeutic concentrations of cytotoxic
agents such as Dox. Although the precise mechanism(s)
as to how β-alanine alters metabolism and chemother-
apy sensitivity remains unknown, our data supports the
hypothesis that alterations in cell energetics is a neces-
sary component of β-alanine’s effect.
Figure 5 β-Alanine suppresses breast epithelial cell migration. (A) Migration measured in Δ percent confluency analyzed as area under the
curve (AUC) of MCF-7 cells following scratch and treatment with 100 mM β-Alanine measured hourly for 24 by phase contrast live cell imaging.
Images on right show in baseline and 24 hour images of MCF-7 migration (top right). (B) Migration measured in Δ percent confluency analyzed
as area under the curve (AUC) of MCF-10a cells following scratch and treatment with 100 mM β-Alanine measured hourly for 24 by phase
contrast live cell imaging. Images on right show in baseline and 24 hour images of MCF-10a migration (bottom right). Images were taken using
10 × magnification. NOTES: * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001 compared with control.
Figure 6 β-Alanine enhances doxorubicin toxicity in malignant
breast epithelial cells. Cell viability of MCF-7 cells treated with
increasing concentrations of Doxorubicin (Dox) in DMSO with and
without 100 mM β-Alanine for 24 hours (final concentration for
DMSO = 0.1%). NOTES: *indicates P < 0.05, **indicates P < 0.01,
***indicates P < 0.001 compared with control (above data = Dox-only
and below data = Dox + β-Alanine). # indicates P < 0.05, ## indicates
P < 0.01 for dose-comparisons of Dox treatment with and
without β-Alanine.
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Figure 7 summarizes the proposed effects that β-alanine
may exhibit on cell metabolism and metastatic phenotype.
Briefly, glucose enters the cell via GLUT1, is metabolized
through glycolysis to pyruvate, and is reduced to form
lactate. Lactate along with protons are exported via mono-
carboxylate transporters decreasing extracellular pH lead-
ing to activation of proteases thereby increasing cell
motility. Decreased extracellular pH in the microenviron-
ment also leads to protonated Dox, thereby impeding cel-
lular uptake and reducing efficacy (shown in Figure 7, left
side) [7,8]. Conversely in β-alanine treated cells, glucose is
taken up and metabolized (possibly at a lesser rate or
magnitude than untreated cells), however both glycolytic
and oxidative metabolism is reduced leading to reductions
in ATP. Additionally, intracellular pH is increased due to
suppression of anaerobic glycolysis, leading to reductions
in lactate, proton production, and migration [6]. Increased
extracellular pH leads to improved Dox transport thereby
increasing efficacy and reducing the minimal therapeutic
dose (shown in Figure 7, right side) [7,8]. It is also im-
portant to mention that we cannot rule out alternative
mechanisms of action of β-alanine, or a possible role of
carnosine resulting in suppressed malignant metabolic
phenotype.
Conclusion
Taken together, our results in combination with previous
observations suggest that β-alanine may elicit several
anti-tumor effects (possibly through carnosine biosyn-
thesis), the mechanisms of which remain ill-defined and
Figure 7 Summary of proposed potential mechanisms of action for intracellular β-alanine in the presence of chemotherapy
Doxorubicin (Dox).
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seemingly tissue-specific. Our observations support the
need for further investigation into the mechanism(s) of
action and specificity of β-alanine in tumor development
and progression.
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